To help us continue to improve our service, this web site uses cookies. They cannot be used to identify you. Using this site implies an agreement to continue accepting them. For more details please see managing the cookies we use.  

Octreotide Case 1 Answers

1) Name the radiopharmaceutical

Octreotide is a synthetic version of somatostatin, originally developed for treating carcinoid syndrome. It is an 8 amino acid peptide and has a longer half-life than somatostatin (2-3hrs vs. 2-3mins). It is usually labelled with 111-indium (called Octreoscan) as 123-iodine has drawbacks and 99m-technetium labelling hasn't been developed yet.

Return to question

Return to home page

The text is entirely the opinion of the author and does not necessarily reflect that of RUH NHS Trust or the Bristol Radiology Training Scheme. Website content devised by Paul McCoubrie.